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Introduction
Low birth weight (LBW) and fetal growth restriction
(FGR) are associated with increased perinatal morbidity
and mortality [1], short-term and long-term childhood
morbidity [2,3], and a range of cardiovascular and
metabolic diseases in later life [4]. Whether we can
predict LBW and FGR prenatally is controversial. Sev-
eral maternal biochemical markers such as pregnancy-
associated plasma protein-A (PAPP-A), human placental
lactogen, and human chorionic gonadotropin (hCG)
are reported to be related to birth weight and gestational
age at delivery, but results were not conclusive [5,6].
PAPP-A is a protein derived from trophoblasts in early
pregnancy. Since fetal growth is known to be correlated
with placental function, there are some reports that low
PAPP-A may be associated with pregnancy complicated
by LBW and FGR [7,8], although this is controversial
[9]. When PAPP-A is combined with maternal age,
maternal serum free `-hCG, and fetal nuchal trans-
lucency (NT) thickness for prenatal screening of Down
syndrome, the accuracy is greater than that of bio-
chemical screening alone in the second trimester. It is
reported that the detection rate for Down syndrome is
89% at a 5% false-positive rate [10]. Currently, this test
is quite popular in our hospital. The aim of this study
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was to investigate whether maternal serum PAPP-A
level in the first trimester can predict LBW and FGR.
Materials and Methods
Sample collection
Between April 1999 and December 2003, we collected
data from all non-smoking women with a singleton
pregnancy who underwent screening for Down syndrome
in the first trimester and who subsequently delivered
at the Cathay General Hospital, Taipei. We excluded
pregnancies in which any of the following was present:
incomplete or incorrect chart record (35 cases),
chromosomal abnormalities (9 cases), major structural
abnormalities (15 cases), abortion at less than 24
weeks’ gestation (23 cases), and major maternal dis-
ease (18 cases). A total of 3,089 pregnancies were en-
rolled into the study.
First-trimester Down syndrome screening
Screening for Down syndrome at 10–13 weeks of
gestation was offered to pregnant women who came
to Cathay General Hospital for prenatal care after
April 1999. Fetal NT thickness and crown–rump length
(CRL) were measured by one of three experienced
sonographers. Fetal NT thickness was measured
when CRL was between 36 and 76 mm, equivalent to
a gestational age of 10 weeks 4 days to 13 weeks 6
days. The procedure followed the criteria published
by the UK Fetal Medicine Foundation [11]. Because the
discrepancy in gestational age calculated from last
menstrual period (LMP) and CRL was quite large in
some pregnancies, we converted the CRL to equivalent
days of gestational age to define the percentile of birth
weight. The equation used, which has been well es-
tablished in our hospital from women with date dis-
crepancy between LMP and CRL of less than 1 week,
is: Predicted gestational age in days = 54.62334 +
0.55155 CRL (mm)
Maternal serum PAPP-A level was determined on the
same day as fetal NT measurement, using a microtiter-
plate enzyme-linked immunosorbent assay according
to the manufacturer’s protocol (Genemed Biotechno-
logies Inc, South San Francisco, CA, USA). Maternal
serum PAPP-A levels are presented as multiples of me-
dian (MoM).
Data analysis
After correction of gestational age using the equation
above, we divided our study population into the following
groups: three FGR groups defined as women with a live
born baby below the 10th, 5th, or 3rd centile, respectively,
of birth weight at the gestational week of delivery; a
LBW group defined as those with infants of birth weight
less than 2,500 g; and a control group of all other
women.
Statistical analysis
The Chi-squared test and t test were used to compare
PAPP-A between subgroups and controls. Multivariate
logistic regression models were built to explore the
relationship among different variables. Receiver
operating characteristic (ROC) curves were drawn to
determine the cut-off MoM values for PAPP-A. A p
value of less than 0.05 was considered statistically sig-
nificant. All statistical analyses were performed using
SPSS version 11.5 (SPSS Inc, Chicago, IL, USA).
Results
In this study, the mean maternal age was 29.8 years
(range, 17–43 years) and 52.1% of women were pri-
migravidae. The mean maternal serum PAPP-A level
was significantly lower in the FGR groups (< 10th centile,
1.03 MoM, p = 0.001; < 5th centile, 0.96 MoM, p <
0.001; and < 3rd centile, 0.99 MoM, p = 0.029) and in
the LBW group (0.98 MoM, p = 0.002) than in the
control group (1.15 MoM) (Table 1).
Table 1. Comparisons of first-trimester maternal serum levels of pregnancy-associated plasma protein-A (PAPP-A)
in groups with a low birth weight infant or fetal growth restriction and normal controls
Birth weight n
PAPP-A (MoM)
Median Mean ( SD t p
Controls 2,773 1.04 1.15 ( 0.65 – –
< 2,500 g 48 0.93 0.98 ( 0.56 3.03 < 0.002
< 3rd centile 92 0.90 0.99 ( 0.60 2.18 < 0.029
< 5th centile 155 0.85 0.96 ( 0.57 3.56 < 0.001
< 10th centile 312 0.91 1.03 ( 0.59 3.35 < 0.001
SD = standard deviation; MoM = multiples of median; t = t test value.
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In the ROC curve analyses, we could not determine
an adequate cut-off value for FGR prediction (Figure),
so we selected 0.3 MoM, 0.5 MoM, and the 5th centile
(0.32 MoM) of PAPP-A as cut-offs to calculate the
relative risks of pregnancy complicated by FGR. Women
with PAPP-A of less than 0.3 MoM or 0.5 MoM had a
higher risk of LBW (OR 2.8, p < 0.001, and OR 2.0, p =
0.001), less than 3rd centile FGR (OR 2.9, p = 0.008,
and OR 1.9, p = 0.027), and less than 5th centile FGR
(OR 2.5, p = 0.005, and OR 1.8, p = 0.007) than the
control group. Likewise, women with a PAPP-A of less
than the 5th centile also had a higher risk of LBW (OR
2.0, p = 0.028), less than 3rd centile FGR (OR 2.3, p =
0.037) and less than 5th centile FGR (OR 2.0, p = 0.021)
than the control group (Table 2). This pattern was not
seen in the 10th centile FGR group. The sensitivities of
detecting pregnancy complicated by LBW and FGR
using 0.3 MoM, 0.5 MoM and the 5th centile of PAPP-
A as cut-offs were up to 10.1%, 22.5%, and 10.1%,
respectively (Table 3).
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Figure. Receiver operating characteristic (ROC) curves of multiples of median (MoM) of pregnancy-associated plasma protein-
A (PAPP-A) predicting birth weight: (A) birth weight < 3rd centile, ROC area = 0.57; (B) birth weight < 5th centile, ROC area =
0.59; (C) birth weight < 10th centile, ROC curve area = 0.55; and (D) low birth weight, ROC area = 0.57.
Table 2. Relative risks of low birth weight and fetal growth restriction at cut-offs for pregnancy-associated
plasma protein-A (PAPP-A) of 0.3 multiples of median (MoM), 0.5 MoM, and the 5th centile
PAPP-A cut-off
Birth weight 0.3 MoM 0.5 MoM 5th centile
OR 95% CI p OR 95% CI p OR 95% CI p
< 2,500 g 2.8 1.5–4.9 < 0.001 2.0 1.3–3.0 0.001 2.0 1.1–3.6 0.028
< 3rd centile 2.9 1.4–5.8 < 0.008 1.9 1.1–3.1 0.027 2.3 1.1–4.7 0.037
< 5th centile 2.5 1.4–4.5 < 0.005 1.8 1.2–2.6 0.007 2.0 1.1–3.6 0.021
< 10th centile 1.2 0.7–2.2 < 0.446 1.2 0.9–1.7 0.197 1.1 0.6–1.8 0.822
OR = odds ratio; CI = confidence interval.
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Discussion
We demonstrated that low first trimester maternal
serum PAPP-A level was significantly correlated with
LBW and FGR. PAPP-A is a maternal serum protein
originally isolated in 1974 by Lin et al [12]. It is derived
from syncytiotrophoblasts [13] and acts as a protease
for binding proteins of insulin-like growth factor (IGFBP-
4) [14]. Since it breaks down IGFBP, resulting in elevation
of free IGFs, low PAPP-A level indicates low IGF level
and, therefore, affects birth weight [14,15]. Maternal
PAPP-A level is high in multiple pregnancies, primi-
gravida pregnancies [16], and intrauterine insemina-
tion pregnancies [17]. A low PAPP-A level reportedly
correlates with smoking [18], abnormal fetal karyotype
[19], early pregnancy failure [5,8,20,21], intrauterine
fetal death [5,7], LBW [8,18,22], FGR [5,7,23,24],
preterm labor [7], and pre-eclampsia [5,25]. However,
Morssink et al reported that the concentration of PAPP-
A in the first trimester is not associated with subsequent
5th centile FGR compared with controls (0.83 MoM vs
0.98 MoM, p = 0.08) [9]. In addition, there is a positive
correlation between PAPP-A level and placental weight
[6,20].
Yaron et al reported that the relative risks of 5th
centile FGR at PAPP-A cut-offs of 0.25 MoM and 0.5
MoM are 3.12 and 3.3, respectively [23]. Similarly,
Smith et al reported that the relative risk of 5th centile
FGR at a PAPP-A cut-off of the 5th centile is 2.9 [7]. The
relative risks of FGR from these two reports were similar
but higher than those of this study (2.5, 1.8, and 2.0 at
PAPP-A cut-offs of 0.3 MoM, 0.5 MoM, and the 5th
centile, respectively).
Although our study showed that a low level of PAPP-
A was associated with a higher relative risk of LBW and
FGR, the sensitivities according to the cut-offs were
quite low. At a PAPP-A cut-off of 0.5 MoM, the sen-
sitivities of detecting subsequent LBW and FGR were
between 16.2% and 22.5%, and the specificities were
around 86%. However, when the PAPP-A cut-off was
0.3 MoM or the 5th centile, the highest sensitivity of
detecting LBW and FGR was only 10.1% with a specificity
of around 96%. Our results were consistent with the
recent report of Kwik and Morris, in which the sensitivity
of detecting 3rd centile and 10th centile FGR were 7.7%
and 10.9%, respectively, for a 0.3 MoM cut-off and
23.1% and 32.7% for a 0.5 MoM cut-off [16]. For this
reason, the maternal serum PAPP-A level was not suf-
ficient to be a single marker to predict LBW and FGR.
Among the cut-offs, 0.5 MoM of PAPP-A seemed to be
better at predicting pregnancies complicated by birth
weight less than the 5th centile or 2,500 g.
In conclusion, we demonstrated that low maternal
serum PAPP-A level in the first trimester was associated
with pregnancy complicated by LBW and FGR, but the
sensitivity was low. As a single marker, PAPP-A is not
sufficient to predict LBW and FGR.
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